Post by Deleted on Aug 14, 2017 13:53:12 GMT
Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
GlobeNewswire•August 14, 2017
ROCKVILLE, Md., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has distributed to shareholders a mid-year update letter reviewing the company’s recent progress and clinical plans for the remainder of 2017.
“Rexahn is at a very exciting point in our clinical development programs with Phase IIa clinical data being generated in several difficult-to-treat cancers,” stated Peter D. Suzdak, Ph.D., Chief Executive Officer of Rexahn. ”We are very encouraged by the Company’s recent progress in our clinical-stage oncology programs and want to keep shareholders updated on our ongoing clinical trials and future plans.”
RX-3117:
•Present additional clinical data from the ongoing Phase IIa trial in metastatic bladder cancer patients who have failed three or more prior therapies
•Initiate a clinical study in metastatic bladder cancer patients in combination with another anti-cancer drug
•Present clinical data from stage 2 of the Phase IIa clinical trial of RX-3117 in metastatic pancreatic cancer patients that have failed three or more prior anti-cancer therapies
•Initiate a combination study with Abraxane® (paclitaxel protein-bound) in newly diagnosed metastatic pancreatic cancer patients
Supinoxin™:
•Present preliminary clinical data from an ongoing a Phase IIa clinical trial in in patients with triple-negative breast cancer
Archexin®:
•Present an update of the Phase IIa clinical trial of Archexin® in patients with metastatic renal cell carcinoma (mRCC)
The Company’s mid-year letter to shareholders is available on the Investor Relations section of its website, investors.rexahn.com.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical-stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company's mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: RX-3117, Supinoxin™, and Archexin®, and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com.
=================================
C L
GlobeNewswire•August 14, 2017
ROCKVILLE, Md., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has distributed to shareholders a mid-year update letter reviewing the company’s recent progress and clinical plans for the remainder of 2017.
“Rexahn is at a very exciting point in our clinical development programs with Phase IIa clinical data being generated in several difficult-to-treat cancers,” stated Peter D. Suzdak, Ph.D., Chief Executive Officer of Rexahn. ”We are very encouraged by the Company’s recent progress in our clinical-stage oncology programs and want to keep shareholders updated on our ongoing clinical trials and future plans.”
RX-3117:
•Present additional clinical data from the ongoing Phase IIa trial in metastatic bladder cancer patients who have failed three or more prior therapies
•Initiate a clinical study in metastatic bladder cancer patients in combination with another anti-cancer drug
•Present clinical data from stage 2 of the Phase IIa clinical trial of RX-3117 in metastatic pancreatic cancer patients that have failed three or more prior anti-cancer therapies
•Initiate a combination study with Abraxane® (paclitaxel protein-bound) in newly diagnosed metastatic pancreatic cancer patients
Supinoxin™:
•Present preliminary clinical data from an ongoing a Phase IIa clinical trial in in patients with triple-negative breast cancer
Archexin®:
•Present an update of the Phase IIa clinical trial of Archexin® in patients with metastatic renal cell carcinoma (mRCC)
The Company’s mid-year letter to shareholders is available on the Investor Relations section of its website, investors.rexahn.com.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical-stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company's mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: RX-3117, Supinoxin™, and Archexin®, and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com.
=================================
C L